Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment

American Journal of Hematology

Volumn 90, Issue 7, 2015, Pages 675-678

  Tvito, Ariella ^a   Bakchoul, Tamam ^b   Rowe, Jacob M ^a   Greinacher, Andreas ^b   Ganzel, Chezi ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; FONDAPARINUX; HIRULOG; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; PREDNISONE; RIVAROXABAN; ANTIBODY; ANTICOAGULANT AGENT; HIRUDIN DERIVATIVE; IMMUNOLOGIC FACTOR; MORPHOLINE DERIVATIVE; PEPTIDE FRAGMENT; POLYSACCHARIDE; RECOMBINANT PROTEIN; THIOPHENE DERIVATIVE;

AGED; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CROSS REACTION; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HIP FRACTURE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOSIS; THROMBOSIS PREVENTION; URINARY TRACT INFECTION; VERY ELDERLY; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; PATHOLOGY; THROMBOCYTE; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

AGED, 80 AND OVER; ANTIBODIES; ANTICOAGULANTS; BLOOD PLATELETS; DALTEPARIN; FEMALE; HIP FRACTURES; HIRUDINS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MORPHOLINES; PEPTIDE FRAGMENTS; PLATELET COUNT; POLYSACCHARIDES; RECOMBINANT PROTEINS; THIOPHENES; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 84931857812     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23971     Document Type: Article

References (25)

1. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998;35(4, Suppl 5):9.
2. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: A systematic review and meta-analysis. Blood 2012;120:4160-4167.
3. Bakchoul T, Zoellner H, Greinacher A. Current insights into the laboratory diagnosis of HIT. Int J Lab Hematol 2014;36:296-305.
4. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005;94:132-135.
5. Kopolovic I, Warkentin TE. Progressive thrombocytopenia after cardiac surgery in a 67 year old man. CMAJ 2014;186:929-933.
6. Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood 2014;123:3651-3654.
7. Krauel K, Poetschke C, Weber C, et al. Platelet factor 4 binds to bacteria, (corrected) inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011;117:1370-1378.
8. Jaax ME, Kruel K, Marschall T, et al. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood 2013;122:272-281.
9. Warkentin TE, Maurer BT, Aster RH. Heparin induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007;356:25.
10. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicenter study with unfractionated heparin. Blood 2005;105:139-144.
11. Warkentin TE, Davidson BL, Buller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011;140:366-373.
12. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed. American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141 (Suppl 2):e495S-e530S.
13. Bhatt VR, Aryal MR, Shrestha R, Armitage JO. Fondaparinux-associated heparin-induced thrombocytopenia. Eur J Haematol 2013;91:437-441.
14. Warkentin TE, Chakraborty AK, Sheppard JI, Griffin DK. The serological profile of fondaparinux associated heparin-induced thrombocytopenia syndrome. Thromb Haemost 2012;108:394-396.
15. Greinacher A, Liebenhoff U, Kiefel V, et al. Heparin-associated thrombocytopenia: The effects of various intravenous IgG preparations on antibody mediated platelet activation-A possible new indication for high dose i.v.IgG. Thromb Haemost 1994;71:641-645.
16. Winder A, Shoenfeld Y, Hochman R, et al. High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: A prompt response. J Clin Immunol 1998;18:330-334.
17. Frame JN, Mulvey KP, Phares JC, Anderson MJ. Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Ann Intern Med 1989;111:946-947.
18. Grau E, Linares M, Olaso MA, et al. Heparin-induced thrombocytopenia-Response to intravenous immunoglobulin in vivo and in vitro. Am J Hematol 1992;39:312-313.
19. Prull A, Nechwatal R, Riedel H, Maurer W. The therapy of the heparin-induced thrombosis-thrombocytopenia syndrome with immunoglobulins. Dtsch Med Wochenschr 1992;117:1838-1842.
20. Betrosian AP, Theodossiades G, Lambrolis G, et al. Heparin-induced thrombocytopenia with pulmonary embolism and disseminated intravascular coagulation associated with low-molecular-weight heparin. Am J Med Sci 2003;325:45-47.
21. Betrosian AP, Theodossiades G, Balla M, et al. Heparin-induced thrombocytopenia: Correction of severe bleeding complication with intravenous immune globulin. Intensive Care Med 2004;30:2136.
22. Cho FN, Liu CB. Potential role of intravenous immunoglobulin in the management of peripartum maternal thrombocytopenia due to various causes. J Chin Med Assoc 2008;71:267-269.
23. Eness EG, Turyan A, Ramazan A, Ismet A. A rare and undesirable complication of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2011;17:546-548.
24. Warkentin TE, Sheppard JA. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood 2014;123:2485-2493.
25. Paran D, Herishanu Y, Elkayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005;16:313-318.